Harmony Biosciences/HRMY

$33.48

3.11%
-
1D1W1MYTD1YMAX

About Harmony Biosciences

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases, as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a molecule with a mechanism of action (MOA) specifically designed to increase histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a major wake-promoting neurotransmitter. The Company also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. Its product candidates also include Zygel, which is a synthetic cannabidiol.

Ticker

HRMY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeffrey Dayno

Employees

246

Headquarters

Plymouth meeting, United States

HRMY Metrics

BasicAdvanced
$1.84B
Market cap
13.17
P/E ratio
$2.47
EPS
0.73
Beta
-
Dividend rate

What the Analysts think about HRMY

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
25.09% upside
High $56.00
Low $30.00
$33.48
Current price
$41.88
Average price target

HRMY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
15.79% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$168.4M
5.12%
Net income
$26.6M
-30.73%
Profit margin
15.79%
-34.13%

HRMY Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.08%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
$0.48
$0.56
$0.63
-
Expected
$0.47
$0.63
$0.65
$0.62
Surprise
1.86%
-11.46%
-3.08%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Harmony Biosciences stock

Buy or sell Harmony Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing